| Literature DB >> 26694354 |
Oana Maria Dragostin1, Sangram Keshari Samal2, Florentina Lupascu3, Andreea Pânzariu4, Peter Dubruel5, Dan Lupascu6, Cristina Tuchilus7, Cornelia Vasile8, Lenuta Profire9.
Abstract
The objective of this study was to develop new films based on chitosan functionalized with sulfonamide drugs (sulfametoxydiazine, sulfadiazine, sulfadimetho-xine, sulfamethoxazol, sulfamerazine, sulfizoxazol) in order to enhance the biological effects of chitosan. The morphology and physical properties of functionalized chitosan films as well the antioxidant effects of sulfonamide-chitosan derivatives were investigated. The chitosan-derivative films showed a rough surface and hydrophilic properties, which are very important features for their use as a wound dressing. The film based on chitosan-sulfisoxazol (CS-S6) showed the highest swelling ratio (197%) and the highest biodegradation rate (63.04%) in comparison to chitosan film for which the swelling ratio was 190% and biodegradation rate was only 10%. Referring to the antioxidant effects the most active was chitosan-sulfamerazine (CS-S5) which was 8.3 times more active than chitosan related to DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging ability. This compound showed also a good ferric reducing power and improved total antioxidant capacity.Entities:
Keywords: antioxidant effects; biodegradation; film; sulfonamide-chitosan derivatives; swelling ratio
Mesh:
Substances:
Year: 2015 PMID: 26694354 PMCID: PMC4691147 DOI: 10.3390/ijms161226204
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Macroscopic images of films: (a) CS-S1 (chitosan-sulfametoxydiazine); (b) CS-S2 (chitosan-sulfadiazine); (c) CS-S3 (chitosan-sulfadimethoxine); (d) CS-S4 (chitosan-sulfamethoxazol); (e) CS-S5 (chitosan-sulfamerazine); and (f) CS-S6 (chitosan-sulfizoxazol).
Figure 2AFM image of chitosan (CS) and of chitosan-sulfadiazine (CS-S2) films.
Figure 3Water contact angle measurements for chitosan-derivative films.
Figure 4Images obtained during the measurements (time zero): chitosan (CS) and CS-sulfamethoxydiazine (CS-S1) films.
Figure 5The strain (mm) of chitosan (CS) and chitosan-derivative films.
Figure 6Swelling ratio of chitosan-derivative films.
Figure 7In vitro biodegradation of chitosan-derivative films.
Figure 8Total antioxidant capacity (EC50 mg/mL) of chitosan derivatives.
Figure 9Ferric reducing power (EC50 mg/mL) of chitosan derivatives.
Figure 10DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging ability (I %) of chitosan derivatives.
Diameter of inhibition area (mm) of chitosan film (CS) and chitosan-derivative films.
| Film | Diameter of Inhibition Area (mm) | |||||||
|---|---|---|---|---|---|---|---|---|
| 16 | 28 | 20 | 20 | 15 | 14 | 0 | 0 | |
| 15 | 30 | 22 | 18 | 19 | 10 | 12 | 17 | |
| 17 | 30 | 27 | 25 | 28 | 20 | 25 | 32 | |
| 18 | 30 | 15 | 20 | 19 | 11 | 0 | 0 | |
| 17 | 30 | 27 | 22 | 22 | 0 | 25 | 32 | |
| 15 | 30 | 20 | 18 | 17 | 0 | 0 | 0 | |
| 17 | 28 | 16 | 18 | 18 | 0 | 0 | 9 | |
S.a.—Staphloccocus auresus ATCC 25923; S.l.—Sarcina lutea ATCC 9341; B.c.—Bacillus cereus ATCC 14579; B.s.—Bacillus subtilis; E.c.—Escherichia coli ATCC 25922; C.a.—Candida albicans ATCC 10231; C.g.—Candida glabrata ATCC MYA 2950; C.s.—Candida sake.
Diameter of inhibition area (mm) of nitrofurantoine and nystatine.
| Control | Diameter of Inhibition Area (mm) | |||||||
|---|---|---|---|---|---|---|---|---|
| Nitrofurantoine 300 µg/disc | 19 | 8 | 12 | 20 | 20 | n.d. | n.d. | n.d. |
| Nystatine 100 µg/disc | n.d. | n.d. | n.d. | n.d. | n.d. | 29 | 26 | 31 |
S.a.—Staphloccocus auresus ATCC 25923; S.l.—Sarcina lutea ATCC 9341; B.c.—Bacillus cereus ATCC 14579; B.s.—Bacillus subtilis; E.c.—Escherichia coli ATCC 25922; P.a.—Pseudomonas aeruginosa CIP 82118; C.a.—Candida albicans ATCC 10231; C.g.—Candida glabrata ATCC MYA 2950; C.s.—Candida sake; n.d.—not determined.